How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer
The Oncotype DX test substantially improves decision accuracy in recommending adjuvant chemotherapy. It may be further improved with a consensus decision. In the case of pre-RS consensus against chemotherapy, the test can be spared.
Authors
- Zsolt Horváth (ORCID: https://orcid.org/0000-0002-5376-7737)
- Gábor Rubovszky (ORCID: https://orcid.org/0000-0003-1723-5589)
- Judit Kocsis (ORCID: https://orcid.org/0000-0002-6110-9750)
- Ákos Sávolt
- Ambrus Kaposi (ORCID: https://orcid.org/0000-0001-9897-8936)
- Balázs Madaras
- Katalin Boér (ORCID: https://orcid.org/0000-0002-5101-7289)
- Gyorgy Benjamin Klément
Institutions
- Semmelweis University (HU)
- Eötvös Loránd University (HU)
- Bács-Kiskun Megyei Kórház (HU)
- Szent János Kórház (HU)
- National Institute of Oncology (HU)
Publication Details
- Journal
- Cancers
- Published
- 2024-08-23
- DOI
- https://doi.org/10.3390/cancers16172928
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.29